Join our daily newsletter At The Bell to receive exclusive market insights
- Healthcare tech developer Jayex Healthcare (JHL) has entered into a trading halt as it plans an upcoming capital raise
- Currently, it is unknown how much the company is aiming to raise or where the funds will be spent
- Company shares will be paused until Monday, May 24, or when the company releases more information about the raise
- On the market, Jayex last traded at 3.6 cents per share on May 19
Jayex Healthcare (JHL) has entered into a trading halt as it plans an upcoming capital raise.
So far it is unknown how much the company is aiming to raise or where the funds will be spent.
Under the trading halt, company shares will be paused until Monday, May 24, or when the company releases more information about the raise.
Jayex is a healthcare tech developer and provides tools needed to improve patient experience.
Earlier this week the company completed the divestment of the Actue hospital queue management business to Canadian medical technology company Vitalhub.
Last month the sale was announced and it will involve Vitalhub acquiring the business, including the hospital contracts in Australia and the United Kingdom.
For the purchase, Jayex will receive £1.3 million (approximately A$2.3 million).
“The sale of Jayex’s on-premises hospital queue management business will enable us to refocus our technology efforts, accelerating other projects such as expanding our core SaaS-based Connect platform not only in the U.K. but also into Australia and New Zealand, as well as further exploring remote patient monitoring (RPM) and other telehealth opportunities,” Chairman Michael Boyd said.
On the market, Jayex last traded at 3.6 cents per share on May 19.
